High-dose Rabeprazole/Amoxicillin Therapy as the Second-line Regimen after Failure to Eradicate H. pylori by Triple Therapy with the Usual Doses of a Proton Pump Inhibitor, Clarithromycin and Amoxicillin

Hepato-Gastroenterology

Volumn 50, Issue 54, 2003, Pages 2274-2278

  Furuta, Takahisa ^a   Shirai, Naohito ^a   Xiao, Fang ^a   Takashita, Misako ^a   Sugimoto, Mitsushige ^a   Kajimura, Masayoshi ^a   Ohashi, Kyoichi ^a   Ishizaki, Takashi ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Amoxicillin; CYP2C19; Helicobacter pylori; Rabeprazole

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; ERADICATION THERAPY; FEMALE; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AMOXICILLIN; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; ENDOSCOPY, DIGESTIVE SYSTEM; FEMALE; GASTRITIS; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PEPTIC ULCER; PROTON PUMPS; RETREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0345392623     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Blaser MJ: Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 1992; 102:720-727.
2. Goodwin CS, Mendall MM, Northfield TC: Helicobacter pylori infection. Lancet 1997; 349:265-269.
3. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345:784-789.
4. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, et al: Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2:1437-1442.
5. Ofman JJ, Etchason J, Fullerton S, Kahn KL, Soll AH: Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med 1997; 126:280-291.
6. Furuta T, Futami H, Arai H, Hanai H, Kaneko E: Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori. J Clin Gastroenterol 1995; 20:S3107-111.
7. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al: Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342:575-577.
8. Sackmann M, Morgner A, Rudolph B, Neubauer A, Thiede C, Schulz H, et al: Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Gastroenterology 1997; 113:1087-1090.
9. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, et al: Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6:639-642.
10. Walsh JH, Peterson WL: The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333:984-991.
11. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdorffer E, O'Morain C, et al: Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996; 1:138-144.
12. Unge P: Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol Suppl 1996; 215:74-81.
13. Sohn DR, Kwon JT, Kim HK, Ishizaki T: Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin Pharmacol Ther 1997; 61:574-582.
14. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al: The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995; 57:662-669.
15. Andersson T: Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31:9-28.
16. Caraco Y, Lagerstrom PO, Wood AJ: Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996; 60:157-167.
17. Ieiri I, Kubota T, Urae A, Kimura M, Wada Y, Mamiya K, et al: Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19ml in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996; 59:647-653.
18. Meyer UA: Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8(Suppl 1):S21-5.
19. Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, et al: Interphenotype differences in disposition and effect on gastrin levels of omeprazole - suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39:511-518.
20. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, et al: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65:552-561.
21. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T: Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001; 70:484-492.
22. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, et al: Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15:1929-1937.
23. Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, et al: CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14:1259-1266.
24. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, et al: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129:1027-1030.
25. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, et al: Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69:158-168.
26. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Nakagawa K, et al: Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001; 11:341-348.
27. Aoyama N, Tanigawara Y, Kita T, Sakai T, Shirakawa K, Shirasaka D, et al: Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. J Gastroenterol 1999; 34:80-83.
28. Tanigawara Y, Aoyama N, Kita T, Shirakawa K, Komada F, Kasuga M, et al: CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999; 66:528-534.
29. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, et al: Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′- hydroxylation status. Clin Pharmacol Ther 1995; 58:143-154.
30. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, et al: CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001; 18:721-727.
31. Williams MP, Sercombe J, Hamilton MI, Pounder RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12:1079-1089.
32. Dent JC, McNulty CA: Evaluation of a new selective medium for Campylobacter pylori. Eur J Clin Microbiol Infect Dis 1988; 7:555-558.
33. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W: Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin - influence on treatment outcome. Am J Gastroenterol 1998; 93:386-389.
34. Maeda S, Yoshida H, Ogura K, Kanai F, Shiratori Y, Omata M: Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance. Gut 1998; 43:317-321.
35. Furuta T, Baba S, Takashima M, Futami H, Arai H, Kajimura M, et al: Effect of Helicobacter pylori infection on gastric juice pH. Scand J Gastroenterol 1998; 33:357-363.
36. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46:594-598.
37. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269:15419-15422.
38. Kubota T, Chiba K, Ishizaki T: Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60:661-666.
39. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC, Jr: Effect of varying pH on the susceptibility of Campylobacterpylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8:888-889.
40. Scott D, Weeks D, Melchers K, Sachs G: The life and death of Helicobacter pylori. Gut 1998; 43(Suppl 1):S56-60.
41. Goddard AF, Jessa MJ, Barrett DA, Shaw PN, Idstrom JP, Cederberg C, et al: Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996; 111:358-367.
42. Midolo PD, Turnidge JD, Lambert JR, Bell JM: Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro. Antimicrob Agents Chemother 1996; 40:1531-1533.
43. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, et al: Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38:402-408.
44. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BI, et al: Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46:198-207.
45. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ: Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999; 9:539-549.
46. Furuta T, Ohashi K, Kobayashi K, Iida I, Yoshida H, Shirai N, et al: Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 1999; 66:265-274.
47. Bayerdorffer E, Miehlke S, Mannes GA, Sommer A, Hochter W, Weingart J, et al: Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995; 108:1412-1417.
48. Miehlke S, Kirsch C, Ochsenkuehan T, Vieth M, Haferland C, Ziegler K, et al:. High-dose omeprazole/ amoxicillin therapy versus quadruple therapy for treatment of Helicobacter pylori resistant against both metroniadazol and clarithromycin: A prospective, randomised cross-over study. Gastroenterology 2001; 120(Suppl):A120.
49. Furuta T, Takashima M, Shirai N, Xiao F, Hanai H, Ohashi K, et al: Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. Clin Pharmacol Ther 2000; 67:684-689.
50. Tsuchiya M, Imamura L, Park JB, Kobashi K: Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull 1995; 18:1053-1056.
51. Kawakami Y, Akahane T, Yamaguchi M, Oana K, Takahashi Y, Okimura Y, et al: In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 2000; 44:458-461.